LAIYANG CITY, China, Feb. 14, 2008 (PRIME NEWSWIRE) -- Genesis Pharmaceuticals Enterprises, Inc. (OTCBB:GTEC) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 10:00 a.m. EST on Tuesday, February 19, 2008 to discuss results for its second quarter ending December 31, 2007 of its Fiscal Year 2008.
Conference Call
Genesis Pharmaceuticals management will host a conference call at 10:00 a.m. Eastern Time on Tuesday, February 19, 2008 to discuss financial results for the second quarter of its Fiscal Year 2008. The conference call will include Mr. Cao Wubo, Chairman and CEO, and Ms Elsa Sung, CFO. To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (800) 688-0796. International callers should call (617) 614-4070. The Conference Pass Code is 21423939. If you are unable to participate in the call at that time, replay of the conference call will be available from Tuesday, February 19 at 12:00 p.m. EST to Tuesday, March 4 at 12:00 p.m. EST. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The Conference Pass Code is 53670554.
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule and granule form. The Company maintains a representative office in the U.S. For more information, refer to http://www.Genesis-China.net.
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.